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Introduction
The past decade has seen major advances in the under-
standing of the pathogenesis of arthritic diseases and has
markedly influenced pharmacological approaches. The
development of inflammatory rheumatic diseases, includ-
ing an initiation phase associated with genetic suscepti-
bilities, the activation of synovial cells and the
development of the pannus are well characterised. Sub-
sequent cartilage and bone destruction leads to an irre-
versible pathology. Osteoarthritis (OA) is far less well
understood, but also leads ultimately to joint tissue
destruction. Hence, a detailed knowledge of the events
underlying these degradative processes is a prerequisite
for all arthritic diseases for the development of therapies
targeting their prevention. Key to this is an understanding
of the proteinases involved in terms of their regulation
and specific function.
This review outlines the detailed studies of the back-
ground biochemistry of the matrix metalloproteinases
(MMPs), which are major players in extracellular matrix
(ECM) turnover in both physiology and pathology. Such
studies are the basis of specific inhibitor development as
potential therapies. The study of metalloproteinase
expression in relation to the progress of different forms
of arthritis is outlined. It is clear that the latter picture is
particularly incomplete, with most studies focused on the
MMPs identified some years ago but rarely focused on
newer potential contributors to the degradative pathol-
ogy of arthritic tissues. Future approaches will need to
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look at the overall patterns of proteinase function in joint
tissues allowing the most precise targeting of new gen-
erations of highly specific inhibitors.
Historical background
Progressive degradation of the ECM that comprises joint
tissues, including articular cartilage, bone and even intra-
articular ligaments and tendons, is a major feature of the
arthritic diseases, leading to permanent loss of function.
Although proteinases of all mechanistic classes play a role
in the degradation of connective tissue macromolecules, it
has long been thought that the major activities involved in
this process belong to the family of MMPs. These enzymes
are secreted by both the resident cells of joint tissues as
well as by invading cells, they are active around neutral
values of pH, and they have the combined ability to degrade
all the components of the ECM (Table 1). MMPs play signifi-
cant roles in both developmental and repair processes, and
it appears that aberrant regulation, which can occur at many
levels (see next section), leads to their hyperactivity in dis-
eases such as rheumatoid arthritis (RA) and OA.
There is now significant evidence for the overexpression of
MMPs in tissues derived from patients with arthritic disease.
Cultures of cells derived from rheumatoid synovia secreted
a collagenolytic activity into the medium [1], and stromelysin-1
[2] and collagenase-1 were detected by immunolocalisation
at sites of cartilage erosion in rheumatoid joints [3]. Both of
these enzymes, as well as the tissue inhibitor of metallopro-
teinase (TIMP)-1, were immunolocalised in synovial samples
from both RA and OA patients [4].
The finding of stromelysin-1 in all synovial samples from
10 patients with different clinical diagnoses and histories,
in contrast to its absence from normal synovia [5], clearly
implicated this enzyme in the arthritic process. It was also
shown that collagenase-1, gelatinase A and matrilysin may
have a role in the synovitis associated with RA, but that
they are not a significant feature in osteoarthritic joints.
Marked regional variations were found in the synthesis of
these MMPs, however, indicating that these diseases are
episodic and that the control of enzyme synthesis is focal.
This indicates the need for further work to colocalise MMP
synthesis with cytokine and matrix expression in synovia
from diseased joints in order to explore further the mecha-
nisms that control the synthesis and degradation of ECM
components of articular cartilage. Stromelysin-1 and colla-
genase-1 have also been measured in the synovial fluids
from rheumatoid and osteoarthritic knee joints [6–8].
Other studies of MMP expression in normal and diseased
cartilage have documented the presence of stromelysin-1,
with lower levels of collagenase-1 [9]. Gelatinase B is
detected as both mRNA and protein in osteoarthritic carti-
lage, but not in normal tissue [10], and is detectable in the
synovial fluid from rheumatoid joints. Collagenase-2 and
collagenase-3 have more recently been identified in
arthritic cartilage [11–14]. Konttinen et al. [15] analysed
the expression of 16 MMPs at the mRNA level in trauma
and RA, and they found some (e.g. collagenase-3 and the
membrane-type matrix metalloproteinase [MT-MMP] MT2-
MMP) exclusively present in the rheumatoid tissue.
The precise targets of MMP action in joint tissues are not
always clear. In particular, there has been extensive
debate concerning their role in the degradation of carti-
lage proteoglycans relative to that of the related family of a
disintegrin, a metalloproteinase and thrombospondin
‘aggrecanase’ (ADAM-TS) [16,17]. Kozaci et al. [18] used
a model system of collagen degradation to conclude that
stromelysin-1, collagenase-2 and collagenase-3 are
unlikely to contribute to proteoglycan degradation, but that
collagenases and gelatinase have major roles in type II col-
lagen breakdown. MT1-MMP is expressed by rheumatoid
synovial fibroblasts and is regulated by tumour necrosis
factor alpha [19]. The identity of the collagenase responsi-
ble for cartilage collagen loss is also still a subject of
detailed study. There is evidence that specific MMP-13
inhibitors can block interleukin-1-induced collagen loss,
and an enhanced cleavage of type II collagen in
osteoarthritic cartilage seems to be correlated with MMP-
13 activity [20].
The MMP family
The MMP family consists of 25 zinc-dependent and
calcium-dependent proteinases in mammalian systems
(Table 1), and MMPs are now thought to be the major pro-
teolytic enzymes that facilitate tissue remodelling in both
physiological and pathological situations [21–23]. The
MMPs do indeed have the combined ability to degrade the
major components of the ECM [24].
MMPs can be classified into at least five main groups,
according to their substrate specificity, primary structure
and cellular localisation; namely, the collagenases, gelati-
nases, stromelysins, matrilysins and MT-MMPs [25]. There
are some MMPs, however, such as macrophage elastase
(MMP-12), stromelysin-3 (MMP-11), MMP-19, enamelysin
(MMP-20), CA-MMP (MMP-23) and epilysin (MMP-28),
that apparently do not fall into any of these categories. In
addition, some enzymes, such as MT1-MMP (MMP-14),
which displays collagenolytic activity and is membrane
associated, may be classified into more than one group.
The collagenases (collagenase-1 [MMP-1], collagenase-2
[MMP-8] and collagenase-3 [MMP-13]) are able to cleave
native triple-helical fibrillar collagens (i.e. type I, type II and
type III) at a single bond, generating characteristic one-
quarter and three-quarter fragments.
Two gelatinases (gelatinase A [MMP-2] and gelatinase B




Matrix metalloproteinases (MMPs) and their substrates
MMP Enzyme Mr latent Mr active Known substrates
MMP-1 Interstitial collagenase 55,000 45,000 Collagens I, II, III, VII, VIII and X, gelatin, aggrecan, versican, proteoglycan 
(collagenase-1) link protein, casein, α1-proteinase inhibitor, α2-M, pregnancy zone protein, 
ovostatin, nidogen, MBP, proTNF, L-selectin, proMMP-2, proMMP-9
MMP-2 Gelatinase A 72,000 66,000 Collagens I, IV, V, VII, X, XI and XIV, gelatin, elastin, fibronectin, aggrecan, 
versican, proteoglycan link protein, MBP, proTNF, α1-proteinase inhibitor, 
proMMP-9, proMMP-13
MMP-3 Stromelysin-1 57,000 45,000 Collagens III, IV, IX and X, gelatin, aggrecan, versican, perlecan, nidogen, 
proteoglycan link protein, fibronectin, laminin, elastin, casein, fibrinogen, 
antithrombin-III, α2M, ovostatin, α1-proteinase inhibitor, MBP, proTNF, 
proMMP-1, proMMP-7, proMMP-8, proMMP-9, proMMP-13
MMP-7 Matrilysin-1 (PUMP-1) 28,000 19,000 Collagens IV and X, gelatin, aggrecan, proteoglycan link protein, fibronectin, 
laminin, entactin, elastin, casein, transferrin, MBP, α1-proteinase inhibitor, 
proTNF, proMMP-1, proMMP-2, proMMP-9
MMP-8 Neutrophil collagenase 75,000 58,000 Collagens I, II, III, V, VII, VIII and X, gelatin, aggrecan, α1-proteinase 
(collagenase-2) inhibitor, α2-antiplasmin, fibronectin
MMP-9 Gelatinase B 92,000 86,000 Collagens IV, V, VII, X and XIV, gelatin, elastin, aggrecan, versican, 
proteoglycan link protein, fibronectin, nidogen, α1-proteinase inhibitor, MBP, 
proTNF
MMP-10 Stromelysin-2 57,000 44,000 Collagens III, IV and V, gelatin, casein, aggrecan, elastin, proteoglycan link 
protein, fibronectin, proMMP-1, proMMP-8
MMP-11 Stromelysin-3 51,000 44,000 α1-proteinase inhibitor
MMP-12 Macrophage 54,000 45,000/ Collagen IV, gelatin, elastin, α1-proteinase inhibitor, fibronectin, vitronectin, 
metalloelastase 22,000 laminin, proTNF, MBP
MMP-13 Collagenase-3 60,000 48,000 Collagens I, II, III and IV, gelatin, plasminogen activator inhibitor 2, aggrecan, 
perlecan, tenascin
MMP-14 MT1-MMP 66,000 56,000 Collagens I, II and III, gelatin, casein, elastin, fibronectin, laminin B chain, 
vitronectin, aggrecan, dermatan sulfate proteoglycan, MMP-2, MMP-13, 
proTNF
MMP-15 MT2-MMP 72,000 60,000 proMMP-2, gelatin, fibronectin, tenascin, nidogen, laminin
MMP-16 MT3-MMP 64,000 52,000 proMMP-2
MMP-17 MT4-MMP 57,000 53,000
MMP-18 Xenopus collagenase 55,000 42,000
MMP-19 54,000 45,000 Collagen IV, gelatin, laminin, nidogen, tenascin, fibronectin, aggrecan, 
COMP
MMP-20 Enamelysin 54,000 22,000 Amelogenin
MMP-21 XMMP (xenopus) 70,000 53,000
MMP-22 CMMP (chicken) 52,000 43,000 Gelatin, casein
(MMP-27)
MMP-23 CA-MMP ? ?
MMP-24 MT5-MMP 63,000 45,000 proMMP-2, proMMP-9, gelatin
MMP-25 MT6-MMP, leukolysin 56,000 Collagen IV, gelatin, fibronectin, fibrin
MMP-26 Matrilysin-2, 28,000 Collagen IV, fibronectin, fibrinogen, gelatin, α1-proteinase inhibitor, 
endometase proMMP-9
MMP-28 Epilysin 59,000 Casein
(55,000)
α2-M, α2-macroglobulin; COMP, cartilage oligomeric matrix protein; MBP, myelin basic protein; Mr, relative molecular mass; TNF, tumour necrosis
factor.
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by a broad spectrum of mesenchymal cells, whereas
gelatinase B is associated with macrophages and periph-
eral blood mononuclear cells, as well as activated connec-
tive tissue cells and tumours. The gelatinases have a
broad substrate specificity and may contribute, together
with collagenases, to the degradation of fibrillar collagens,
basement membrane components and stromal ECM mole-
cules (e.g. fibronectin).
Stromelysins (stromelysin-1 [MMP-3] and stromelysin-2
[MMP-10]) have one of the broadest substrate spectra of
the MMPs and can degrade most ECM components, such
as gelatin, fibronectin, laminin and aggrecan, but not triple-
helical collagens. They are expressed by synovial fibro-
blasts from a rheumatoid joint but not by normal synovial
cells. Stromelysin-3 (MMP-11), however, has weak proteo-
lytic activity and is activated intracellularly by a furin-like
convertase. Both these properties distinguish it from the
other two members of the stromelysin group.
Although matrilysins (matrilysin-1 [MMP-7] and matrilysin-
2 [MMP-26]) lack the hinge region and the COOH-
terminal, hemopexin-like domain common to almost all
other members of the MMP subfamily, they are potent pro-
teinases. Matrilysin-1 is expressed by a range of benign
and malignant tumours, whereas matrilysin-2 was only
recently cloned and detected in uterus, placenta and
endometrial tumours.
The group of six cell-associated MT-MMPs (MT1-MMP
[MMP-14], MT2-MMP [MMP-15], MT3-MMP [MMP-16],
MT4-MMP [MMP-17], MT5-MMP [MMP-24] and MT6-
MMP [MMP-25]) seems to be activated intracellularly by a
furin-type proprotein convertase. With the exception of
MT4-MMP and MT6-MMP, which are membrane bound
via a glycosylphosphatidyl-inositol molecule and not via a
transmembrane domain, these enzymes also contain a
COOH-terminal cytoplasmic tail.
MT1-MMP was shown to be a major activator of
proMMP-2 on the cell surface. This activation is thought to
be facilitated via a ternary complex of MT1-MMP, TIMP-2
and proMMP-2, enabling cells (e.g. tumour cells) to invade
stromal tissue or to cross the basement membrane of
blood vessels during metastasis. With the exception of
MT6-MMP, which is predominantly expressed in leuko-
cytes, the other MT-MMPs are found in many cell types,
although they have not as yet been rigorously studied in
relation to arthritic tissues.
Structure and function of MMP domains
MMPs are multidomain proteins consisting of a signal
peptide, a propeptide, and the catalytic and COOH-
terminal domains, as shown in Figure 1. MT-MMPs and
gelatinases have additional features such as a COOH-
terminal transmembrane region followed by a short cyto-
tail, and three fibronectin type II repeats in the catalytic
domain, respectively.
All MMPs are translated with a NH2-terminal hydrophobic
sequence of 18–30 residues that is responsible for
trafficking of the enzyme through the endoplasmic reticu-
lum and the Golgi apparatus, and for its subsequent
secretion into the extracellular space. The signal peptide is
cleaved off during the secretion process. Interestingly, the
signal peptide in CA-MMP (MMP-23) contains a trans-
membrane motif that anchors the enzyme to the mem-
brane. Activation and secretion is achieved by cleavage in
a proprotein convertase recognition sequence located
between the propeptide and the catalytic domain.
The propeptide domain, N-terminal to the catalytic domain,
consists of about 80 residues arranged in three α-helices,
and it is responsible for enzyme latency. This domain con-
tains the sequence motif PRCGVPD (also called the ‘cys-
teine switch’ motif), which is highly conserved among
MMPs. In the latent enzyme, the propeptide domain is
located directly opposite the active site cleft and coordi-
nates the catalytic zinc ion with the thiol of the cysteine
residue, thus preventing binding of a water molecule
required for peptide hydrolysis [26]. Apart from the direct
coordination of the zinc ion, several β-structure-like inter-
Arthritis Research    Vol 4 Suppl 3 Murphy et al.
Figure 1
Basic domain structures of the matrix metalloproteinases (MMPs).
MMPs consist of: a propeptide (grey), which maintains the enzymes in
a latent state; a catalytic domain (blue) with the active site and the
catalytic zinc (Zn) (red); and, with the exception of the matrilysins, a
COOH-terminal domain (C) (yellow) with homology to the serum
protein hemopexin. The latter two domains are connected by a linker
peptide. Gelatinases have an insert of three fibronectin type II repeats
(turquoise) in the catalytic domain, which is involved in substrate
recognition. Membrane-type MMPs contain a transmembrane domain
(black) and a cytoplasmic tail (green) at the COOH terminus, which
anchors these enzymes in the cell membrane.
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chain hydrogen bonds are formed between the propeptide
and the catalytic site, similar to the bonds established with
substrates and inhibitors. It should be noted, however, that
the binding orientation of the propeptide is the opposite to
that of the substrate
All MMPs (except the MT-MMPs, stromelysin-3 and
epilysin, which are activated intracellularly by a furin-type
proprotein convertase) probably become activated in a
stepwise manner outside the cell by proteolytic cleavage.
Activating proteases, like MMPs, serine or cysteine pro-
teinases, attack the so-called ‘bait region’, an exposed and
flexible stretch of around 30–40 residues, which probably
results in destabilisation of the cysteine switch–zinc inter-
actions [26]. These molecular rearrangements promote
the full activation of the enzyme by exposing the final
cleavage site between propeptide and catalytic domain,
generally around residues 80–90, to proteolytic cleavage.
The activation of proMMPs (e.g. by other proteinases and
MMPs) will be discussed in more detail later.
The MMP catalytic domain consists of approximately
160–170 residues and contains the active centre with the
catalytic zinc ion, responsible for substrate hydrolysis and
inhibitor interactions. As already described, three con-
served histidine residues in the HExxHxxGxxH motif,
located 50–55 residues from the COOH-terminal end of
the domain, ligate the catalytic zinc ion. X-ray analysis of
various MMP catalytic domains, some of which complexed
with an inhibitor (i.e. collagenase-1, stromelysin-1,
matrilysin-1, collagenase-2 and MT1-MMP), revealed high
structural similarity among enzymes.
Essentially, the MMP catalytic domain is made up of a
twisted β-sheet covering two long α-helices (helix A and
helix B), and of a separate helix at the COOH-terminal end
of the domain. The sheet itself consists of four parallel β-
strands (strand I, strand II, strand III and strand V) and one
antiparallel β-strand (strand IV) (Fig. 2). In addition to the
catalytic zinc, a second zinc ion (the so-called ‘structural
zinc’) and one to three calcium ions (depending on the
MMP) are also bound in this domain and seem necessary
for its function. Two of the three histidine residues coordi-
nating the active site zinc are located within helix B,
whereas the third histidine is located in the loop between
helices B and C and lies opposite the other two histidine
residues (Fig. 2).
The typical MMP active site cleft, carved into the surface
of the ellipsoidal domain, is relatively flat on the left-hand
side (nonprimed) and contains the catalytic zinc in its
centre, but is deep on the right-hand side (primed) [27].
Studies using peptide substrates revealed that a substrate
is fixed to its cognate MMP through seven intermain-chain
hydrogen bonds and that the scissile peptide bond car-
bonyl group is directed towards the catalytic zinc ion to be
strongly polarised. For the mechanism of substrate hydrol-
ysis by MMPs, it was proposed that the glutamic acid
residue within the HExxHxxGxxH motif then polarises a
water molecule for a nucleophilic attack on the carbonyl
carbon atom of the substrate scissile amino bond.
The sequence requirements for a certain substrate to be
cleaved depend on the depth and structure of the catalytic
site of the MMP. For example, dominant hydrophobic inter-
actions are made through P1′ and P3 residue side chains
of the substrate and the respective pockets in the MMP.
P1, P2, P3, etc. and P1′, P2′, P3′, etc. indicate peptide
substrate residues in the NH2-terminal and COOH-termi-
nal directions from the scissile bond, respectively,
whereas S1, S2, S3, etc. and S1′, S2′, S3′, etc. indicate
the opposing subsites of the MMP [27].
In general, proline and leucine residues at the P3 and P2
positions of the substrate, respectively, are the preferred
amino acids for MMPs. A large residue in the P1′ position
of the substrate is also preferential for binding to the MMP
active site. This residue interacts with the so-called ‘speci-
ficity pocket’ (S1′ pocket), a deep cavity within the MMP
active site. The S1′ pocket is a varied structural feature in
the active site of MMPs, and it has a major influence on
substrate and inhibitor specificity. Stromelysin-1 and MT1-
Available online http://arthritis-research.com/content/4/S3/S039
Figure 2
Structure of the catalytic domain of the matrix metalloproteinase MMP-
3. The ribbon diagram was created using WebLab Viewer software
based on a crystal structure analysis by Gomis-Rüth et al. [61].
Strands (sI–sV) and helices (hA–hC) are labelled in black; the catalytic
zinc (centre), coordinated by three histidine residues (pink), and the
structural zinc (Zn) (top) are labelled in black and white, respectively;
and the NH2 terminus (N) and COOH terminus (C) are labelled in red.
The active site cleft and the characteristic methionine (Met) turn are
indicated with arrows.
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MMP both have very deep hydrophobic S1′ pockets and
prefer residues with aliphatic or aromatic side chains in
the P1′ position of the substrate. In fact, synthetic pep-
tides containing unusual amino acids with extremely long
side chains in the P1′ position were hydrolysed by MT1-
MMP and stromelysin-1 with higher efficiency than pep-
tides containing natural amino acids in the same position.
Collagenases
Studies on the catalytic domains of the collagenases have
shown that they contribute to the specificity for the cleav-
age of triple-helical collagen. We investigated exon 5 of
collagenase-1 in this respect by exchanging it with the
exon 5 of the noncollagenolytic proteinase MMP-3. Exon 5
harbours major features of the active site including the
three histidine ligands of the functional zinc, the S1′
binding site and components of the other substrate
binding sites, S2′, S3′ and S1–S3. The overall exon 5
sequence shows a high degree of similarity between colla-
genase-1 and stromelysin-1. The major variations include
the greater hydrophilicity of collagenase-1 and its slightly
smaller size. Hence the exchange of exon 5 causes no
predictable major structural changes.
The exon 5 mutant of collagenase-1 did demonstrate a
change in peptide substrate and small inhibitor specificity
as well as binding to N-TIMP-1, the three active N-terminal
loops becoming more stromelysin-1-like. The exon 5
mutant also lost most of its ability to cleave type I collagen
as well as a reduction in gelatin turnover, indicating that
the active site cleft is itself a determinant of specific col-
lagenolytic capacity [28].
A unique feature of the catalytic domain of gelatinases A
and B is the presence of three fibronectin type II repeats
just upstream of the zinc binding motif, contributing
around 20 kDa to the size of the enzyme. These repeats
are located between strand V and helix B of the MMP cat-
alytic domain, consist of two double-stranded antiparallel
β-sheets and two large irregular loops each, and are
important for binding of the substrate in the active site. It
was demonstrated that recombinantly expressed repeats
bind to denatured type I collagen, denatured type IV and
type V collagens, elastin and native type I collagen. While
deletion of the three repeats in MMP-2 resulted in
decreased gelatinolytic activity and abrogated binding to
collagen, TIMP binding was not affected.
Between the catalytic domain and the COOH-terminal
hemopexin-like domain lies a variable stretch of 2–72
amino acids, which is termed the ‘linker’ or ‘hinge region’.
This region is very extended in the case of collagenases,
being rich in proline residues and possibly being responsi-
ble for activity versus fibrillar collagens. A hypothetical
mechanistic contribution of these linker peptides has been
postulated, whereby the proline-rich peptides adopt a
helical conformation that might ‘unwind’ the helix. We
analysed the hinge region of collagenase-2 by alanine
mutagenesis and found that this region had a pronounced
effect on the stability and collagenolytic activity of the
enzyme. Notably, some proline residues (shown under-
lined) were modified to alanine in the sequence Gly-Leu-
Ser-Ser-Asn-Pro-Ile-Gln-Pro-Thr-Gly-Pro-Ser-Thr-Pro-Lys-
Pro, to show that they were critical to the collagenolytic
mechanism [29].
The MMP COOH-terminal domain has strong sequence
similarity with the serum protein hemopexin and consists
of approximately 200 amino acids. It has the shape of an
ellipsoidal disk, as demonstrated by X-ray analysis of the
crystal structures of this domain in porcine collagenase-1,
human gelatinase A and human collagenase-3. The
domain consists of four β-sheets (blades I–IV) with very
similar structure, each consisting of four antiparallel β-
strands, which are arranged almost symmetrically around
a central core. The overall appearance is that of a four-
bladed propeller, whereby the innermost strands of all four
blades are arranged almost parallel to each other, building
a central channel that contains Ca2+ and Cl– ions. The sta-
bility of this structure is ensured by a disulfide bond
between blades I and IV, which is conserved in all MMPs.
The role of the C-terminal hemopexin-like domain varies
widely according to the MMP, one of the most notable
being the ability to interact with fibrillar collagens. The
hemopexin-like domain of stromelysin-1 was shown to
bind to type I and type II collagen, although neither can be
cleaved by stromelysin-1. In contrast, all collagenolytic
enzymes appear to require the hemopexin-like domain for
hydrolysis of triple-helical collagens. In our laboratory, we
have prepared C-terminal domain deletion mutants of coll-
agenases, gelatinase A and MT1-MMP to show that, in
each case, the domain is absolutely required for ‘specific
collagenolysis’ (i.e. cleavage of type I collagen helix 3/4
from the N-terminus) to occur [3–8].
Mutants of the collagenases comprised of the prodomain
and catalytic domain are peptidolytic on removal of the
propeptide, but cannot cleave native fibrillar collagen.
Cleavage of other collagens (e.g. type IV collagen) by col-
lagenase-3 and other matrix macromolecules does not
seem to require the C-terminal domain. Furthermore,
‘exchange’ of C-terminal domains between MMPs (e.g. N-
terminal collagenase-1–C-terminal MMP3, N-terminal col-
lagenase-3–C-terminal MMP-19) generates proteinases
that either do not exhibit specific collagen cleaving poten-
tial or, in the case of collagenase-3, gelatinase A and
gelatinase A-stromelysin-1, exhibit much reduced activity
[28,30,31] (Knäuper et al., unpublished data).
Gelatinase A is a remarkable ‘collagenase’, although it acts
very slowly on native collagens relative to denatured forms.
Arthritis Research    Vol 4 Suppl 3 Murphy et al.
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We found that deletion of the collagen–gelatin binding
type II fibronectin-like domain caused a loss of the ability of
MMP-2 to cleave gelatin efficiently or to bind to collagen or
gelatin [32,33]. However, cleavage of native collagen still
absolutely required the presence of the C-terminal domain
rather than the fibronectin-like domain. Indeed, the mecha-
nism of MMP-2 cleavage of collagen proceeds in two
phases: the first resembling that of the interstitial collage-
nases, and the second being gelatinolysis [31].
The COOH-terminal domain is thus necessary for activity
of the collagenases versus fibrillar collagens, but it does
not appear to be important for substrate specificity of
most other MMPs. McQuibban et al. recently reported a
physiological substrate of gelatinase A, monocyte
chemoattractant protein-3, however, which was discov-
ered using the gelatinase A hemopexin-like domain as bait
in the yeast two-hybrid system [34].
We have constructed and expressed recombinant forms
of gelatinase B in which the C-terminal domain has been
deleted to compare the activation, catalytic and TIMP
binding properties with the full-length enzyme. In vitro, the
truncated MMP-9 and wild-type MMP-9 behaved identi-
cally when activated by organomercurial or stromelysin-1.
When we assessed activation in a cell-based system
using either plasminogen or stromelysin-1, both forms of
MMP-9 activated at similar rates. Furthermore, the active
form of C-truncated gelatinase B showed similar kinetics
to wild-type gelatinase B for the turnover of peptide sub-
strates and gelatin. Indeed, the only differences in the
behaviour of truncated MMP-9 and full-length MMP-9 was
found to be in the rate of binding to TIMP-1.
Full-length TIMP-1 inhibited gelatinase B in a biphasic
manner, with a rapid first phase yielding 50–70% inhibi-
tion, apparently dependent on the particular enzyme
preparation, followed by a slow phase. In comparison, the
C-truncated gelatinase B binding to TIMP-1 was difficult
to analyse as the data were suggestive of an isomerisation
of the enzyme–inhibitor complex [35]. It was apparent that
binding of TIMP-1 was severely abrogated by the lack of
the C-terminal domain of gelatinase B, reducing the value
of the association constant by one to three orders of mag-
nitude [35]. In comparison, association of both forms of
gelatinase B with N-TIMP-1 in which the three C-terminal
loops have been deleted gave binding constant values
similar to those of the slow phase of wild-type TIMP-
1–gelatinase B binding. TIMP-2, however, does not show
any discrimination in its binding to different forms of gelati-
nase B. No biological explanation for the ‘special’ associa-
tion between TIMP-1 and gelatinase B has been
established.
Studies on the domains of gelatinase A have been quite
extensive. The effect of deletion of the fibronectin type II-
like domain was, to some extent, discussed earlier under
collagenases. Apart from a role in the binding of the
enzyme to collagen and the turnover of gelatin, this
domain does not appear to be required for the turnover of
peptide substrates or for the binding of low molecular
weight active site inhibitors or TIMPs [32].
The effect of deletion of the C-terminal domain of pro-
gelatinase A and the loss of ability to cleave native colla-
gen was also discussed earlier. It has also been shown
that the C-domain of gelatinase A is essential for its
binding and activation at the surface of many cell types. It
has been established that this involves the ability of the C-
domain of gelatinase A to interact quite tightly with the
inhibitor TIMP-2 as a complex with the membrane-associ-
ated MT1-MMP [36–38]. Kinetic studies of the domain
interactions between TIMP-2 and gelatinase A show very
fast association rates between the full-length proteins that
are markedly abrogated by truncation of the TIMP-2 to the
N-terminal three loops or of the gelatinase A to remove the
C-terminal domain. TIMP-2 binding to the C-domain of
gelatinase A is very tight and can occur in the absence of
catalytic domain interactions in progelatinase A. The
binding has two identifiable components: a charged inter-
action (salt sensitive) involving the C-terminal tail of the C-
terminal three loops of TIMP-2, and a hydrophobic
interaction between the remainder of the TIMP-2 and the
C-domain of gelatinase A [39].
Our analyses of domain motif function in the membrane-
associated MT1-MMP have shown that the C-terminal
domain is required for collagenolysis, as already
described [40]. Kinetic studies with the TIMPs, however,
have shown that the C-domain plays a negligible role in
TIMP interactions. TIMP-1 has very little ability to inhibit
MT1-MMP for reasons that are not yet entirely clear.
However, TIMP-2, TIMP-3 and TIMP-4 are effective
inhibitors, either as full-length forms or as the N-terminal
three loops, against full-length or C-truncated MT1-
MMP. Hence, the complexes of TIMPs with MT1-MMP
are all theoretically able to bind the C-domain of MMP2
simultaneously since the necessary binding sites should
remain available.
One difference between the MT-MMPs and other MMP
family members is the insertion of eight amino acids
between strands βII and βIII in the catalytic domain (163-
PYAYIREG-170 in MT1-MMP). To investigate the role of
this region of MT1-MMP in its function, we have made a
number of mutations and deletions in this region. The motif
appeared to have no role in the cleavage of peptide sub-
strates or extracellular proteins such as fibrinogen or in the
binding of TIMP-2. However, the motif is involved in inter-
actions with progelatinase A, facilitating both the solution-
phase MT1-MMP activation mechanism as well as that at
the cell surface [41].
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The collagenase-3 C-terminal domain deletion abrogates
fibrillar collagen cleavage as already discussed, but has
no effect on its ability to interact with peptide substrates
or inhibitors. Association with TIMP-1, TIMP-2 or TIMP-3
is marginally decreased, suggesting that C-domain inter-
actions are not of great significance [42]. This is of inter-
est in the light of the observation that the activation of
collagenase-3 mediated by cell-associated MT1-MMP
requires the presence of the C-domain of collagenase-3
[42]. The mechanism underlying this observation remains
to be elucidated.
Interactions of the MMPs with their specific natural
inhibitors, the TIMPs, predominantly involve the enzyme
catalytic domains and the N-terminal three disulfide-
bonded loops of the TIMPs. Motifs within these two inter-
acting domains determine a degree of specificity between
individual MMPs and TIMPs but these are not well charac-
terised. The C-domain interactions of certain MMPs with
the three C-terminal disulfide-bonded loops of the TIMPs,
however, do seem to play a major role in the acceleration of
association rates in ways that may be biologically relevant.
We have focused our studies on the interactions of TIMPs
with MT1-MMP (see earlier) because they are involved in
the mechanism for MT1-MMP activation of progelatinase
A, apparently bridging the two proteinases to form a tri-
molecular complex. We found that one specific interaction
between TIMP-2 and MT1-MMP could be demonstrated
between the hairpin turn of the A and B β strands of
TIMP-2 and MT1-MMP. Detailed site-directed mutagen-
esis of the AB loop showed the residue Tyr36 is almost
wholly responsible for the binding of this region to
MT1-MMP [43].
We also recently extended our observations to compare
TIMP-2 with TIMP4. TIMP-2 and TIMP-4 have a number of
similar characteristics with respect to sequence and kinet-
ics of MMP-2 and MT1-MMP interaction, but the latter
does not support MT1-MMP activation of progelatinase A.
A series of TIMP-4 mutants were produced, including
chimeric proteins with TIMP-2 and forms of the C-terminal
charged tail that contained sequences from TIMP-2. In
biochemical and cell-based studies, we found that TIMP-4
chimeras containing the C-domain of TIMP-2, and even
TIMP-4 C-tail mutants containing elements of the TIMP-2
C-tail sequence (Arg186-Pro195), were able to support
the formation of gelatinase A–MT1-MMP trimolecular com-
plexes and to support gelatinase A activation (Knäuper et
al., unpublished data).
In conclusion, MMPs have a domain structure to facilitate
their interaction with activators, substrates and inhibitors.
Specific binding to cell membrane or ECM components
may also be determined by these domains. These are of
importance to focus proteolytic activities at specific peri-
cellular sites. For each MMP, a detailed analysis of the
relationship between the function of its domains and their
specific structure will give valuable new data to aid the
design of future novel and specific antiproteinase mole-
cules as potential therapeutics. The mutagenesis and
kinetic studies that we have performed have indicated the
extent of the task and, with the advent of all the relevant
crystal structures, further directed studies may proceed.
MMP cleavage of ECM components
The MMP family contains the only vertebrate proteinases
that can specifically degrade triple-helical collagens type I,
type II and type III, as described earlier. Cleavage character-
istically and specifically occurs at a single locus in all three
collagen chains, at a point approximately three-quarters
from the N-terminus of the molecule. At physiological tem-
perature, the cleaved triple helix then unwinds, becoming
susceptible to attack from other, less specific, proteinases.
The precise MMPs responsible for cartilage collagen
cleavage in the arthritides is still open for debate. There
are obvious differences in the turnover of collagen
between OA and RA with respect to the location of early
changes. This may suggest that a different MMP is pre-
dominantly responsible for collagen cleavage and that the
involvement of different metalloproteinases is temporally
distinct in each disease. Changes within the subchondral
bone appear to precede cartilage changes in deep layers
of cartilage, with subsequent fibrillation of the articular
surface in OA. In contrast, early changes in RA appear in
the surface layers with the majority of cartilage collagen
destruction occurring at the cartilage–pannus junction,
although changes within the cartilage matrix may precede
and allow penetration by synovial cells.
Collagenase-1 and collagenase-3 are both made by chon-
drocytes (as are collagenase-2, gelatinase A and MT1-
MMP), while collagenase-1 is also produced by the
synovial fibroblasts. Hence, some workers consider colla-
genase-1 may be the foremost collagenase in RA, where
the synovium proliferates to form a pannus that can invade
cartilage, while collagenase-3 may predominate in OA
where the chondrocyte drives the cartilage destruction
[13,20,44]. Collagenase-2, previously thought to be
restricted to neutrophils, has recently been described in
chondrocytes [11] and in synovial cells [45], but a role in
cartilage collagen destruction is still unproven [15]. MT1-
MMP and gelatinase A (along with all the collagenases)
have also been localised to the invading rheumatoid
pannus, suggesting a possible role for either (or both)
enzymes in disease [46].
MMPs and therapeutic strategies
MMP activity is controlled at several levels, of which gene
expression is arguably the most important and is modu-
lated by a variety of growth factors and cytokines [47]. A
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number of individual polymorphisms of MMP genes have
recently been described with some disease associations
[48], and associations with arthritic diseases may emerge
in future research. After secretion, the activation described
earlier (i.e. the proteolytic removal of the propeptide from
the latent enzyme) represents one critical step in control-
ling MMP activity in the ECM. Once activated, regulation
in the ECM is effected by natural inhibitors, such as the
TIMPs and α2-macroglobulin [49]. The balance between
MMP levels and TIMP levels is thought to be of great
importance in determining levels of proteolysis.
Potential strategies for the modulation of MMPs include
the development of effectors at the level of gene induction
(cytokine inhibitors, receptor antagonists, signal transduc-
tion), production (transcription, secretion), zymogen acti-
vation (inhibit activating enzyme or prevent conversion of
proactive to active enzyme) or enzyme activity (production
of TIMPs or inhibition by small molecules). The potential of
signal transduction inhibitors for the treatment of arthritis
was recently discussed [50] and future directions in the
treatment of OA at the level of MMPs has been sum-
marised by Malemud and Goldberg [51].
The direct inhibition by synthetic low molecular weight enti-
ties that bind to the zinc and other features of the catalytic
site of the enzyme has been most vigorously pursued
[17,52]. Early developments led to inhibitors of relatively
poor specificity. However, the availability of crystal struc-
tures for a number of MMPs has allowed the design and
production of inhibitors with increased specificity.
The issue of which MMP (or which other metallopro-
teinase, such as ADAM-TS4/5 with aggrecanase activity)
to inhibit still remains. Van Meurs et al. found that active
MMPs, particularly stromelysin-1, played a pivotal role in
cartilage destruction in both the immune-mediated
complex model of arthritis and in antigen-induced arthritis
models. Absence of stromelysin-1 did not affect aggrecan
depletion in arthritis but did prevent the appearance of
collagen cleavage products and cartilage erosions
[53,54], suggesting a role for stromelysin-1 in the activa-
tion of procollagenases. Elliot and Cawston [55] and Clark
et al. [22] discuss the issue of whether it is preferable to
inhibit the degradation of the proteoglycan or the collagen
component of cartilage as a therapeutic strategy for arthri-
tis, but the question of the precise target enzymes
remains. There is some support for the concept that the
use of a broad-spectrum MMP inhibitor that also inhibits
the ADAM proteinases (e.g. TACE, ADAM 17) would be
most appropriate in arthritis therapy [55,56].
MMP inhibitors have frequently exhibited toxicity in clinical
trials, however, with the development of musculo-skeletal
problems such as arthralgia, myalgia and tendinitis. These
were predominantly in the upper limbs and were
reversible. Interestingly, it has been shown that MT1-
MMP-deficient mice not only develop dwarfism and
osteopaenia, but also arthritic symptoms and soft tissue
fibrosis, demonstrating the important function of this MMP
in normal tissue remodelling and suggesting that it would
be advantageous to selectively inhibit MMPs active within
disease contexts [57].
There are currently no synthetic MMP inhibitors in clinical
trials for arthritis due to the failure of early studies, for
reasons such as those already outlined. A tetracycline
derivative, doxycycline, in subantimicrobial doses (Perio-
stat; CollaGenex Pharmaceuticals Inc., Newtown, PA,
USA) is currently the only MMP inhibitor approved by the
US Food and Drug Administration and is used as an
adjunct therapy in adult periodontitis. The use of tetracy-
clines for the treatment of arthritic diseases is limited,
although doxycycline has been shown to improve some
disease parameters as well as reducing the levels of colla-
genase activity in some patients with RA [58,59].
Concluding remarks
There are now 25 known MMPs, as detailed in this review,
but many have not been substantially characterised in rela-
tion to arthritic diseases. It will be important for such
studies to be carried out in relation to specific disease
states. Although it is likely that the MMPs identified are
major players, others could have subtle but critical activi-
ties in relation to the tissue cells and their interaction with
their environment. A proteomics approach [60] should
prove useful, if these techniques become sensitive
enough, to document the range of proteinases expressed,
followed by more detailed studies using quantitative RT-
PCR in relation to well-documented disease status. Spe-
cific abrogation of individual MMPs in model systems may
then give clues vital to the focusing of the design of
antiMMP agents as potential therapies.
Glossary of terms
ADAM-TS = a disintegrin, a metalloproteinase and throm-
bospondin ‘aggrecanase’; ECM = extracellular matrix;
MMP = matrix metalloproteinase; MT-MMP = membrane-
type matrix metalloproteinase; TIMP = tissue inhibitor of
metalloproteinases.
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